創新創業商務計畫

Abstract

銨弘生醫是一家擁有高效率藥物開發平台的新藥開發公司，專注於開發雙功能分子調控蛋白質降解機制BIGPRO (Bi-functional liGand induced PROteolysis) ，透過藥物提升降解致病蛋白質的效率；藥物開發工作在銨弘生醫自主建立的 AIMCADD (Auto-bio-Informatic-MedChem-Computer-Aid Drug Design) 模組化技術平台，結合自動化、生物資訊、藥物化學、電腦輔助藥物設計及完整新藥研發和藥物優化的能力，旨在透過高速且精準的藥物設計與自動化篩選技術，可以快速篩選出藥物標的並優化藥物，加速新藥研發，成為新藥研發領域最佳策略性夥伴，共同開發未被滿足的醫藥需求。

銨弘生醫的商業模式將採取彈性及互利的商業合作模式，以簽訂合約的方式在不同開發階段早期授權予合作夥伴或選擇適合的合作夥伴建立策略聯盟，讓銨弘生醫成為早期即可以有營收的新藥開發公司，銨弘生醫的研發成果能夠與全球多數僅專注於生物標的篩選、藥物臨床開發的公司或大藥廠合作開發藥物，以達到優勢相加乘且風險分攤的合作模式，共同開發具有潛力的候選藥物（Drug candidates）；此商業模式從 2015年至 2020 年年初已被 4 家蛋白質降解劑技術公司證實其可行性，且這些公司陸續和許多大藥廠簽訂總數高達數十億美元金額的合作開發藥物案子；相較於一般小分子藥物，蛋白質降解劑技術具有眾多優勢，除可以消除治病蛋白質，更有潛力將蛋白質降解劑技術應用到另外 80% 仍無藥可治的藥物標的；綜觀全球市場，此蛋白質降解劑技術仍在剛起步階段，銨弘生醫可以運用特有的AIMCADD高效率藥物開發平台，快速搜尋出適合的生物標的，並設計成雙功能分子調控蛋白質降解的BIGPRO藥物。銨弘生醫將切入包含癌症、神經退化性疾病、老化相關疾病與感染性疾病等。

基於銨弘生醫團隊過去在台灣從事藥物開發的成功經驗，銨弘生醫會依據個別藥品的市場分析，擬定國外各地區的開發策略，包括自行開發計畫、權利轉移或共同開發等，這些彈性策略將讓銨弘生醫能夠在 3 年內達到損益平衡，並在 4-5 年內帶來可觀的利潤。以銨弘生醫經營團隊豐富的藥物開發成功經驗，結合具有良好國際關係且專注於臨床藥物開發的公司以及政府經費的支持，相信未來將可在泛太平洋地區之新藥開發領域上佔有重要的地位及優勢。

銨弘生醫計劃在台灣設立控股公司，並於 4-5年內選擇利於公司長期營運的資本市場股票公開上市。在上市之前，銨弘生醫至少將完成 5 項正式的交易合約，其中合作對象是國際性的大藥廠，為公司帶來實際利潤。銨弘生醫是一個以新藥研發為主軸的生醫公司，其近程與中程目標將致力於研發癌症及神經退化性疾病的新藥。同時，銨弘生醫亦會利用團隊在藥物優化的的經驗及能力，依市場機能的可行性、合作夥伴的方向和生技公司以共同研發的模式策略合作，以期在3年內實現獲利。

以一個投資者而言，銨弘生醫是一個值得投資的對象，因為它擁有已被證實可行的技術平台以及新藥產品，同時公司具備在台灣新藥開發業界首屈一指及具有爆發力的研發團隊。而一般新成立的生技公司，它們的技術可能是新的或尚未被證實過的，因此有其風險。銨弘生醫透過團隊2個月的時間建立AIMCADD及實際驗證，快速篩選出數個適合用來設計蛋白質降解藥物的生物標的並建立初步先導藥物，證明銨弘生醫的產品、經驗與專業知識，更值得投資人信賴，這些經驗與知識是生技公司與跨國性大藥廠最有價值的資產。

AnHone is a leading biotech company specializing in new drug research called BIGPRO (Bi-functional liGand induced PROteolysis). The BIGPRO drug is an enabler to increase the speed of protein degradation processes that ultimately reach the balanced protein level. AnHone develops the research platform called AIMCADD (Auto-bio-Informatic-MedChem-Computer-Aid Drug Design) that integrates the knowledge of bioinformatics, medical chemistry, and lead optimization into an automotive output. The platform creates a synergy of hit-to-lead and lead optimization process where generates the new pipeline for the biotech and the multinational pharmaceutical companies. The role of AnHone is to be the best research partner with those companies working together to fulfill the unmet medical needs.

The business model will keep in high-flexibility and a cost-risk sharing collaboration model with the strategic alliances. The upstream development results at different stages generate out-licensing or joint-development project opportunities signed with the partners, in return for the milestone payments to AnHone. A similar business model has been put in practice since 2015. We can see a growing trend from 2015 to 2020, four companies in protein degradation research have signed the contracts up to 1 billion US dollar with multinational pharmaceutical companies by a series of payments at different milestones. Although the business model seems to be at an early rising stage, the technology has been proved to treat the root cause of the disease and to reach 80% of the undruggable target. Hence, AnHone sees 2020 as the best timing to enter the market.

The focused therapeutic area in 3-5 years is in cancer, neurodegenerative, and the aging diseases whereas AnHone contributes strong expertise in upstream drug development. The research output at different milestone stages will later out-license to other biotech companies or become joint-development projects depending on the partnership model with the customers.

Our team possesses a sustainable track record in drug discovery and the development field, covering the expertise of upstream drug discovery, market analysis, business development, out-licensing and joint-development research...etc. AnHone, unlike the traditional biotech companies, will be achieving the financial break-even in three years. In 4-5 years, the company will bring the revenue up to TWD$400 Million by accomplishing minimally 5 contracts with the multinational pharmaceutical companies. We have a strong mission to become the leading biotech company in JAPAC and create a difference in the drug discovery field.

AnHone is a good investment portfolio for investors among the startup biotech companies. AnHone positions itself as a first-in-class drug discovery company with strong pipelines and validated technology platforms in a short time of development. We aim to provide valued products, knowledge, and the long-term partnership to our biotech partners and the pharmaceutical companies.